Actinium Pharmaceuticals, Inc. (ATNM)
| Market Cap | 213.12M |
| Revenue (ttm) | 81,000 |
| Net Income (ttm) | -48.82M |
| Shares Out | 29.40M |
| EPS (ttm) | -1.83 |
| PE Ratio | n/a |
| Forward PE | 6.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 297,427 |
| Open | 7.73 |
| Previous Close | 7.74 |
| Day's Range | 7.20 - 7.82 |
| 52-Week Range | 4.00 - 9.86 |
| Beta | 0.08 |
| Analysts | Strong Buy |
| Price Target | 25.72 (+254.76%) |
| Earnings Date | May 13, 2024 |
About ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical... [Read more]
Financial Performance
In 2023, ATNM's revenue was $81,000, a decrease of -92.14% compared to the previous year's $1.03 million. Losses were -$48.82 million, 47.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ATNM stock is "Strong Buy." The 12-month stock price forecast is $25.72, which is an increase of 254.76% from the latest price.
News
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
- The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis - Represents...
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a multi-billion market with six FDA approved therapies totaling sales over $3.5 billion...
PanTera signs a second agreement for the supply of actinium-225
PanTera's continues to deploy its strategy to become a market leader into the production and distribution of Ac225
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Actinium's cyclotron produced Actinium-225 material has demonstrated radiochemical and radionuclidic purity identical to current gold-standard methods and has the potential to be significantly lower c...
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
- Active relapsed or refractory AML patients 65+ years receiving an Iomab-B led Bone Marrow Transplant (BMT) achieved significant improvement in survival at one and two years compared to control arm p...
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) ...
NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)
BELOIT, Wis. & VANCOUVER, British Columbia--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225.
NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors
BELOIT, Wis. & CHESTER SPRINGS, Pa.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement.
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
- Two oral presentations and three poster presentations will highlight Iomab-B and Iomab-ACT CD45 targeted conditioning for bone marrow transplant and CAR-T cellular therapy NEW YORK , Jan. 2, 2...
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
Relapsed or refractory AML patients with TP53 mutation known to have dismal outcomes due to limited effective treatment options Median Overall Survival of 5.49 months observed in patients with a TP53 ...
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Oral presentation highlighted Iomab-B improves overall survival in patients with TP53 mutation with active, relapsed or refractory AML Eighth oral presentation of the Phase 3 SIERRA results at ASH con...
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
Oral presentation to highlight Iomab-B's ability to significantly improve overall survival in patients with relapsed or refractory AML with a TP53 mutation Four presentations in total demonstrating th...
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
Actimab-A can target CD33 positive immune suppressing myeloid derived suppressor cells and restore T cell proliferation and effector response Solid tumor MDSC infiltration and uptake of Actimab-A conf...
Actinium Appoints Lynn Bodarky as Chief Business Officer
- Senior leader with proven track record of executing business development and licensing transactions totaling $5 billion at multinational pharmaceutical and biotechnology companies NEW YORK , N...
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it ...
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
- Relapsed or refractory AML patients with a TP53 mutation receiving Iomab-B led allogeneic bone marrow transplant had a median Overall Survival of 5.49 months compared to 1.66 months in patients...
Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
- Ongoing clinical trial is the first ever to combine targeted radiotherapy conditioning, Iomab-ACT, with CAR-T cell therapy to achieve lymphodepletion along with reduction of cytokine release syndrom...
Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
NEW YORK , Sept. 27, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details an abstr...
Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO
- Extended follow-up in the Actimab-A + CLAG-M trial showed median overall survival in patients proceeding to bone marrow transplant of 24 months in all patients and 30 months in patients who received...
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting
- First ever data demonstrating anti-leukemic effect of Actimab-A in FLT3 Mutant AML models NEW YORK , Aug. 31, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actiniu...
NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
BELOIT, Wis. & CHESTER SPRINGS, Pa.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Curadh MTR sign a strategic long term supply agreement for n.c.a. therapeutic radioisotope actinium-225 (Ac-22...
Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress
NEW YORK, Aug. 21, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details two abstra...
Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
NEW YORK , July 24, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that th...
NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)
BELOIT, Wis. & ROCHESTER, Minn.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Nucleus RadioPharma sign a supply agreement for alpha-emitting therapeutic radioisotope actinium-225 (Ac-225).
SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data
- SNMMI Henry N. Wagner, Jr., Abstract of the Year award represents top selection out of more than 1,500 abstracts accepted for presentation NEW YORK , June 26, 2023 /PRNewswire/ -- Actinium Pharmaceu...